These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide.
    Author: Blayney DW, Goldberg DA, Leong LA, Margolin KA, Burke JS, Doroshow JH.
    Journal: Cancer; 1993 Apr 01; 71(7):2351-7. PubMed ID: 7680946.
    Abstract:
    BACKGROUND: In an attempt to improve the complete remission and cure rate of advanced, bulky, high-risk germ cell cancer in men, a "high-dose" cisplatin, vinblastine, bleomycin, and etoposide (PVeBV) regimen was introduced. METHODS: Ten men with biopsy-proven germ cell tumors who had one or more poor prognostic features were treated with PVeBV. RESULTS: Six of the 10 had complete remissions and are long-term survivors. The most devastating toxicity, which resulted in the death of three patients, was progressive respiratory failure. It was postulated that renal tubular injury prolonged the renal clearance of bleomycin, intensifying the patient's pulmonary exposure to this drug and increased the susceptibility to pulmonary injury at lower than expected cumulative doses of bleomycin. CONCLUSIONS: Modifications of the regimen to reduce toxicity without diminishing the efficacy should be considered before PVeBV is adopted for general use.
    [Abstract] [Full Text] [Related] [New Search]